Pss41 - Secukinumab Significantly Reduces Psoriasis-Related Work Impairment and Indirect Costs Compared to Ustekinumab and Etanercept in Tunisia
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2541
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV